secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001437749-24-021219
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica Expands DM199 into Preeclampsia with Phase 2 Trial Starting Q4 2024
-----------------------------------------------------------------------------

- Phase 2 open-label, single-arm, investigator-sponsored trial enrolling up to 120 preeclampsia/FGR patients; first subject Q4 2024, topline results H1 2025.
- Trial cost estimated at ~$1.5M; led by Prof. Catherine Cluver (Stellenbosch Univ.) with collaboration from Prof. Stephen Tong (Univ. Melbourne).
- DM199 did not cross the placental barrier in rat studies; prior REDUX CKD data showed SBP reduction of 12.6 mmHg (p=0.004) in patients with baseline SBP ≥140 mmHg.
- No approved therapeutics for preeclampsia in US/Europe; DM199 is a large-molecule protein (rhKLK1) that may improve placental perfusion and reduce hypoxia.
- Company to host KOL event on July 29, 2024; conference call on June 27, 2024 at 8:00 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924021219/0001437749-24-021219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924021219/dmtp20240624_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-021219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer